Elanor Commercial Property Fund

ECF

Elanor Commercial Property Fund is a real estate investment trust. The company is headquartered in Sydney, New South Wales. The company went IPO on 2019-12-06. The Fund invests in commercial properties located in major metropolitan areas or established commercial precincts. The Fund's objective is to provide strong, risk-adjusted returns through a combination of regular distributions and capital growth. To achieve this objective, the Fund's strategy is to invest in commercial office properties with differentiated competitive market positions that are located in major metropolitan areas or established commercial precincts; execute leasing strategies and actively manage the properties to grow the income and capital value of the assets; acquire additional high investment quality commercial office properties in line with the Fund's investment criteria, and maintain a conservative capital structure with a target gearing range between 30% and 40%. The firm is managed by Elanor Funds Management Limited.

Echelon Resources Limited

ECH

New Zealand Oil & Gas Ltd. engages in the production and exploration of crude oil, natural gas, liquefied petroleum gas, and light oil. The Company’s portfolio includes a spread of wholly and partly owned onshore and offshore oil and gas assets, in Australia, New Zealand and Indonesia. The company owns stakes in several producing and exploration assets located in Australia’s Amadeus and Perth Basins, which includes Mereenie, Palm Valley, and Dingo. Its projects in New Zealand include Kupe gas and light oil field and Maari oil field. Its interests in Indonesia are with its subsidiary, Cue Energy Resources Ltd (Cue). Cue has production from two fields, Mahato in central Sumatra and Sampang in East Java, produces mainly gas. The Palm Valley field is in one permit over 100 kilometers west of Alice Springs in Australia’s Northern Territory. Dingo is a gas field consisting of about 469 square kilometers L7 permit. Its segments include Perth Basin, Kupe oil & gas field (Kupe), Amadeus Basin oil & gas fields, and Cue Energy Resources Limited.

Ebos Group Limited

EBO

EBOS Group Ltd. engages in the provision of healthcare and animal care products and services. The firm is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care, and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services, and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. The company sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.

EBR Systems Inc.

EBR

EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. The company is headquartered in Sunnyvale, California. The company went IPO on 2021-11-24. The firm is engaged in developing and commercializing Wireless Stimulation Endocardially (WiSE), an implantable, cardiac pacing device able to provide stimulation to endocardial (inside the heart) heart tissue for the correction of heart rhythm conditions without requiring the use of leads. WiSE offers leadless solutions for LV Pacing, including cardiac resynchronization therapy (CRT) and conduction system pacing (CSP). The firm also offers CRT devices through the CRM subsegment under the brand names, including Visionist X4 CRT-P, Valitude X4 (CRT-P), Momentum CRT-D, Resonate X4 CRT-D, and Vigilant X4 CRT-D, among others. The firm operates various subsidiaries, which include EBR Systems (AUST) Pty. Ltd. and EBR Systems (UK) Limited, which establish clinical trials in Australia and the United Kingdom, respectively.